文献速递妇科

TRIO-15多中心开放标签II期研究:ganitumab治疗复发性铂敏感卵巢癌的疗效与安全性结果

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2023-01-27

TRIO-15是一项多中心开放标签II期研究,评估ganitumab(AMG 479)在铂敏感复发性卵巢癌中的疗效与安全性。61例患者接受18 mg/kg ganitumab每3周一次,客观缓解率为8.2%(95%CI 3.1-18.8),临床获益率80.3%,中位无进展生存期2.1个月,中位总生存期21个月。最常见不良事件为疲乏(36.1%)和高血压(34.4%)。结论认为ganitumab耐受良好,但结果不支持在未选择的卵巢癌患者中进一步研究ganitumab单药。

要点

  • 61例铂敏感复发性卵巢癌患者接受ganitumab 18 mg/kg每3周一次,客观缓解率8.2%(95%CI 3.1-18.8)。
  • 临床获益率80.3%(95%CI 67.8-89.0%),中位无进展生存期2.1个月(95%CI 2.0-3.1),中位总生存期21个月(95%CI 19.5-NA)。
  • 常见不良事件为疲乏(36.1%)和高血压(34.4%),3级不良事件以高血压(11.5%)和超敏反应(8.2%)最常见。

核心结论

  • ganitumab耐受良好,但结果不支持在未选择的卵巢癌患者中进一步研究ganitumab单药。

研究设计与样本

  • 多中心、开放标签、II期研究,评估ganitumab(AMG 479)在铂敏感复发性卵巢癌患者中的疗效与安全性。
  • 患者为初级铂类治疗后CA125进展(GCIG标准)或RECIST可测量病灶,接受ganitumab 18 mg/kg每3周一次。
  • 主要终点为独立放射学审查委员会(IRC)按RECIST 1.1和/或GCIG CA125标准评估的客观缓解率(ORR)。
  • 次要终点包括临床获益率(CBR)、无进展生存期(PFS)和总生存期(OS)。
  • 共入组61例患者。

主要发现

  • 客观缓解见于5/61例患者(ORR 8.2%,95%CI 3.1-18.8),其中RECIST部分缓解1例、完全缓解2例,CA125标准部分缓解2例。
  • 临床获益率为80.3%(95%CI 67.8-89.0%)。
  • IRC按RECIST评估的中位PFS为2.1个月(95%CI 2.0-3.1)。
  • 按RECIST IRC和/或CA125评估的中位PFS为2.0个月(95%CI 1.8-2.2)。
  • 中位OS为21个月(95%CI 19.5-NA)。

关键数值与推荐

  • 最常见总体不良事件为疲乏(36.1%)和高血压(34.4%)。
  • 1/2级高血糖发生于30.4%的患者。
  • 3级不良事件以高血压(11.5%)和超敏反应(8.2%)最常见。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IGF signaling has been implicated in the pathogenesis and progression of ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a fully human monoclonal antibody against IGF1R that blocks binding of IGF1 and IGF2, were evaluated in patients with platinum-sensitive recurrent OC. METHODS: Patients with CA125 progression (GCIG criteria) or measurable disease per RECIST following primary platinum-based therapy received 18 mg/kg of ganitumab q3w. The primary endpoint was objective response rate (ORR) assessed per RECIST 1.1 by an independent radiology review committee (IRC) and/or GCIG CA125 criteria. Secondary endpoints included clinical benefit rate (CBR), progression free survival (PFS) and overall survival (OS). RESULTS: 61 pts. were accrued. Objective responses were seen in 5/61 patients (ORR 8.2%, 95% CI, 3.1-18.8) with 1 partial response (PR) by RECIST and 2 complete responses (CR) as well as 2 PR by CA125 criteria. CBR was 80.3% (95% CI, 67.8-89.0%). The median PFS according to RECIST by IRC was 2.1 months (95% CI, 2.0-3.1). The median PFS per RECIST IRC and/or CA125 was 2.0 months (95% CI, 1.8-2.2). The median OS was 21 months (95% CI, 19.5-NA). The most common overall adverse events were fatigue (36.1%) and hypertension (34.4%). Grade 1/2 hyperglycemia occurred in 30.4% of patients. Hypertension (11.5%) and hypersensitivity (8.2%) were the most frequent grade 3 adverse events. CONCLUSIONS: IGF1R inhibition with ganitumab was well-tolerated, however, our results do not support further study of ganitumab as a single agent in unselected OC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Davidson TM, Lebreton CL, Hendricksen AEW, et al. Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2023. PMID: 36709663. doi:10.1016/j.ygyno.2023.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。